Abstract
Irbesartan belongs to a group of angiotensin II receptor blockers that are used worldwide for the treatment of patients with hypertension, type 2 diabetes, and impaired renal function. Irbesartan can be administered alone or in combination with other antihypertensive drugs (for example, hydrochlorothiazide), if blood pressure control cannot be achieved with monotherapy. The mechanism of action of Irbesartan is mainly due to the selective blockade of AT1 receptors and, as a consequence, a decrease in the vasopressor effect of angiotensin II. The review article summarizes pharmacokinetic and pharmacodynamic properties and clinical data on the tolerability and safety of Irbesartan.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.